Skip to main content
. 2021 Jun 4;12:685343. doi: 10.3389/fmicb.2021.685343

Figure 1.

Figure 1

Prevalence of emm type, ssa+, and erythromycin-resistant (ErmR) isolates in 2008–2019. (A) The emm type of ssa+ isolates in 2008–2019. (B) Prevalence of emm1-type, emm12-type, ssa+, and ErmR isolates in 2008–2019. (C) Prevalence of emm1 and emm12 ssa+ isolates in 2008–2019. (D) Prevalence of emm1 and emm12 ErmR isolates in 2008–2019.